Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-EARLY extension study of acoramidis in newly diagnosed ATTR-CM
NL-OMON59735Phase 3Not yet recruiting
- Sponsor
- Eidos Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and transthyretin amyloidosis (ATTR), sponsored by Eidos Therapeutics. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Adverse events leading to discontinuation and 4 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON59735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59735.